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Background: Selection of an appropriate patient-reported outcome (PRO) instrument for a clinical trial requires
knowledge of the instrument’s responsiveness to detecting treatment effects. The purpose of this study was to
examine the responsiveness of two health-related quality of life (HRQL) instruments used in clinical trials involving
HIV-infected adults: the HIV-targeted Medical Outcomes Study HIV Health Survey (MOS-HIV), and a generic measure,
the EuroQol-5D (EQ-5D).
Methods: A systematic review identified clinical trials using the MOS-HIV or EQ-5D to assess outcomes for HIV-
infected adults. Data abstracted from each study included study type, treatment regimen(s), PRO results, and effect
size (either reported or calculated). Effect size was calculated as the difference between baseline and follow-up
mean scores divided by the baseline standard deviation. Magnitude was categorized as small (d=0.20), medium
(d=0.50), and large (d=0.80).
Results: Between 2005 and 2010, the MOS-HIV was administered in 12 trials. Significant differences were observed
between groups and over time in physical health summary (PHS) and mental health summary (MHS) scores
(P<0.05) in subjects switching therapy after experiencing Grade-2 adverse events. Effect sizes were medium
(0.55 and 0.49 for PHS and MHS, respectively) among treatment-naïve adults beginning therapy (two studies), but
negligible among treatment-experienced adults (0.04 and 0.13 for PHS and MHS, respectively; three studies). The
EQ-5D was used in five trials between 2001 and 2010. It was responsive to occurrences of adverse events and
opportunistic infections, with small-to-medium effect sizes (range 0.30–0.50) in each of its five dimensions.
Conclusions: A systematic review of PRO study results showed both the MOS-HIV and EQ-5D were responsive to
changes between groups and/or over time in treatment-naïve HIV-infected patients. These instruments may be
used either individually or together in clinical trials to measure changes in HRQL.
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The use of highly active antiretroviral therapy (HAART)
has improved survival of persons with HIV infection to
the extent that HIV-disease is now considered a chronic
condition, with treatment goals focused on optimizing
health-related quality of life (HRQL) rather than only on
improving survival. Therefore, understanding the impact* Correspondence: kristy.hanson@unitedbiosource.com
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reproduction in any medium, provided the orof HAART regimens on HRQL has become increasingly
important to patients and their healthcare providers.
Furthermore, as regulatory requirements for drug ap-
proval have become more stringent [1], authorities are
paying close attention to the use of HRQL measures in
clinical trials and the subsequent claims that are made
based on the trial results.
A comprehensive review of the literature by Clayson
et al. (2006) [2] identified and evaluated all HRQL in-
struments—both generic and HIV-targeted—reported in
the HIV/AIDS literature between 1990 and 2005. We. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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HRQL instruments used in clinical trials evaluating non-
nucleoside reverse-transcriptase inhibitors (NNRTI)-
based regimens from 2005–2010. We then selected one
HIV-targeted HRQL instrument, the Medical Outcomes
Study HIV Health Survey (MOS-HIV), and one generic
HRQL instrument, the EQ-5D, for detailed assessment.
Both instruments are widely used in clinical trials and
observational studies and are translated into more than
20 languages [3,4]. While the MOS-HIV was the first
HIV-targeted instrument developed specifically for use
in HIV/AIDS populations, the EQ-5D has also been used
patients with advanced HIV disease, typically alongside
one or more HIV-specific measures.
Given the growing importance of HRQL in HIV-
infected patients while remaining cognizant of the bur-
den associated with administering PRO instruments in
clinical trials, it is important to carefully evaluate and se-
lect the most sensitive and appropriate HRQL measures
for implementation in clinical trials. Therefore, the study
was conducted to understand the responsiveness of the
MOS-HIV and EQ-5D instruments in clinical trials of
HIV-infected adults.Methods
Literature search
A systematic review identified clinical trials adminis-
tering the MOS-HIV or EQ-5D and evaluating HIV-
infected adults from 2005–2010, or earlier when fewer
than five studies were identified during that period, as
was the case with the EQ-5D. Since only three studies
were identified from 2005–2010, the search for EQ-5D
studies was expanded to 2001–2010, so that at least five
studies could be reviewed. Our search strategy included
a combination of Medical Subject Headings (MeSH)
terms for HIV [HIV OR HIV infections], instrument
names [Euroqol, EQ-5D, MOS-HIV], and clinical trial
Publication Types [clinical trial OR clinical trial, phase
IV OR clinical trial, phase III OR clinical trial, phase II
OR controlled clinical trial OR randomized controlled
trial]. We limited our search to articles written in English
with abstracts available. In addition to the PubMed search,
we conducted a manual search of the bibliographies of
the electronically-identified primary studies and review
articles.Study selection
The inclusion and exclusion criteria for studies to be in-
cluded in our systematic review were established prior
to conducting the literature search. Reviews, editorials,
animal studies, and those reporting results of children
were excluded from our analysis. All identified articles
were initially screened by two authors to excludeduplicates, citations that were clearly irrelevant, and
those which did not contain the PRO instruments of
interest.
Data extraction
Data abstracted from each study included study type,
treatment regimen(s), PRO results, and effect size (either
reported or calculated). Effect size was calculated as the
difference between baseline and follow-up mean scores
divided by the baseline standard deviation and was
interpreted as small (d=0.20), medium (d=0.50), and
large (d=0.80) [5]. Statistical significance of results is
presented as reported in the original studies; the authors
did not calculate or estimate the statistical significance
of findings. Where possible, results are aggregated and
summarized across studies. Additional results are sum-
marized and presented by study design (randomized
controlled trial and non-randomized controlled trials).
Description of instruments
The MOS-HIV can be administered via survey or inter-
view in approximately 5–10 minutes. The MOS-HIV as-
sesses ten dimensions of HRQL encompassing the
following scales: general health perceptions, physical
functioning, role functioning, social functioning, pain,
energy/fatigue, health distress, mental health, cognitive
functioning, and overall quality of life [6]. The scales of
the MOS-HIV are scored as summated rating scales on a
0–100 scale where higher scores indicate better health [7].
Combining some of the dimensions, MOS-HIV phy-
sical health summary (PHS) and mental health summary
(MHS) scores are also generated on a scale of 0–100,
with higher scores indicating better health status [8].
The use of summary index scores rather than multiple
scale scores simplifies data analysis and the interpret-
ation of findings from clinical trials and aids in compari-
sons across studies [9]. While all scales contribute to the
calculation of the PHS and MHS scores, certain scale
scores contribute most strongly. Specifically, the physical
function, pain, and role function scale scores contribute
most strongly to the PHS score, and the mental health,
health distress, quality of life, and cognitive function
scales contribute most strongly to the MHS score. The
vitality, general health and social function scales con-
tribute to both factors. Summary scores are transformed
to t-scores with a mean of 50 and a standard deviation
of 10 [7].
The EQ-5D, developed by the EuroQol Group and ori-
ginally referred to as the Euroqol instrument, is a five-
item instrument with one question assessing each of five
dimensions: mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression. In the version of the
EQ-5D used in the studies assessed here, each of the five
EQ-5D dimension has three levels, ranging from ‘no
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2, or 3 for each of the dimensions to establish an indi-
vidual’s health state; there are a total of 243 health states
for all possible response combinations. EQ-5D health
states may be converted into a summary index by apply-
ing a formula that attaches weights to each of the levels
in each dimension and deducting the appropriate
weights from a score of 1 [10]. Index scores range from
0 to 1 where higher scores indicate better health. The
EQ-5D may also include a visual analog scale (VAS) that
assesses overall health. VAS scores range from 0 to 100
and higher scores indicate better health.
To improve the instrument’s sensitivity and reduce
ceiling effects, the EuroQol Group recently introduced a
five level version of the EQ-5D, named the EQ-5D-5L
[11]. However, all studies reported in this review utilized
the three level (EQ-5D-3L) version of the instrument;
hence, all references to the EQ-5D in this review refer to
the three level version of the instrument.
Results
MOS-HIV
Between 2005 and 2010, the MOS-HIV was adminis-
tered in 12 clinical trials (nine randomized and three
non-randomized prospective controlled trials). Summa-
rized across studies, the MOS-HIV demonstrated the
ability to detect change over time in both physical and
mental health summary scores among treatment-naïve
adults initiating antiretroviral (ARV) therapy (mean ef-
fect sizes 0.55 and 0.49, respectively). This was not seen




Bucciardini et al. 2007 [13] ddI/d4T/EFV 4.7
ddI/d4T/NFV 0.7
ddI/d4T/EFV/NFV 2.0
Stangl et al. 2007a [23] HAART + weekly home visits 15.0*
Average for treatment-naïve patients [weighted] 2.5
Nuesch et al. 2009b [17] Continuous treatment −1.3
Scheduled treatment interruptionsc −1.2
Huang et al. 2008 [14] TPV/r (tipranavir / ritonavir) 0.2
CPI/r (boosted comparitor PI) −0.3
Powers et al. 2006 [18] Intermittent groupd 0.6
Continuous groupe 1.0
Average for treatment-experienced patients [weighted] −0.2
Overall mean [weighted] 0.7
Mean change calculated as final score – baseline score. % change calculated as [(fin
score – baseline score) / standard deviation of baseline score.
*P<0.05; Note: significance of mean change scores not available for all studies; aPro
treatment-naïve and treatment-experienced patients (analyzed together); cCD4-guid
ARV therapy; d7 cycles of 4 weeks off/8 weeks on HAART; eContinue HAART regimethree HIV studies evaluating therapy modifications in
treatment-experienced adults (Table 1).
Table 2 presents an overview of MOS-HIV physical
and mental health summary scores in the identified
studies. Additional study details (e.g., study objective,
population characteristics, clinical and PRO results in-
cluding results of MOS-HIV subscales) are available in
the Additional file 1: Appendix. Corresponding with
Table 2, results of each of the 12 clinical trials are de-
scribed in detail below.
Randomized controlled trials
A study by Chang et al. (2007) [12] evaluated the effect
of adding the relaxation response to usual acupuncture
treatment in HIV-infected adults. From baseline to 12-
week follow-up, the mean MHS score increased 10.6
points (P<0.001) and the PHS score increased 8.1 points
(P<0.01) in the intervention group (P<0.01); no signifi-
cant differences were observed in the control group. In
addition, there was a clinically significant seven-point
difference in the energy subscale of the MHS.
A study by Bucciardini et al. (2007) [13] compared the
initiation of didanosine (ddI)/stavudine (d4T)/efavirenz
(EFV) versus ddI/d4T/nelfinavir (NFV) versus ddI/d4T/
EFV/NFV in treatment-naïve HIV-infected adults over
three years. The trial found both no significant diffe-
rences over time and no significant differences between
treatment groups in MOS-HIV scores.
Three studies evaluated treatment regimens containing
protease inhibitors (PIs). Huang et al. (2008) [14] com-
pared tipranavir/ritonavir (TPV/r) versus a comparatorment naïve and treatment-experienced HIV-infected
sical health summary Mental health summary
nge % change Effect size Mean change % change Effect size
9.4% −0.43 4.0 8.2% −0.40
1.5% −0.05 2.8 5.8% −0.28
4.2% −0.17 0.0 0.0% 0.00
38.3% −1.53 14.2* 35.5% −1.27
0.1 −0.55 2.3 0.1 −0.49
−2.4% 0.20 0.8 1.5% 0.03
−2.2% 0.19 0.4 0.8% −0.15
0.4% −0.02 1.4 2.9% −0.13
−0.6% 0.03 1.7 3.6% −0.17
1.1% −0.07 3.2* 5.9% −0.37
1.9% −0.09 3.2 5.9% 0.00
0.0 0.04 1.5 0.0 −0.13
0.1 −0.19 1.8 0.1 −0.27
al score - baseline score) / baseline score] × 100. Effect size calculated as (final
spective non-randomized controlled trial; bPatient population includes
ed treatment with threshold of 350 cells/μL for interruption/re-initiation of
n for 22 weeks.
Table 2 Summary of MOS-HIV physical and mental health summary scores in NNRTI clinical trials
Citation Treatment/dosing regimen Follow-up
period























treatments prescribed by their
acupuncturists, listened to tapes
with instructions to elicit the
relaxation response via earphones,
followed by soft music played
in the clinic
4 weeks 57.5 (21.1) 61.3 N N 57.5 (17.0) 62.9 Y N
8 weeks 62.7 N N 62.8 N N





to soft music played in the
clinic
4 weeks 62.0 (21.4) 66.7 N N 64.1 (17.9) 71.0 Y N
8 weeks 66.4 N N 69.5 N N
12 weeks 65.7 N N 70.7 N N
Bucciardini
et al. (2007)
Didanosine + stavudine +
efavirenz
1 year 50 (11) 54.7 N N 49 (10) 53.0 N N
2 years 54.9 N N 50.4 N N
3 years 54.9 N N 49.5 N N
Didanosine + stavudine +
nelfinavir
1 year 46 (13) 46.7 N N 48 (10) 50.8 N N
2 years 49.2 N N 51.5 N N
3 years 50.9 N N 53.5 N N
Didanosine + stavudine +
efavirenz + nelfinavir
1 year 48 (12) 50.0 N N 50 (9) 50.0 N N
2 years 48.1 N N 49.5 N N
3 years 50.0 N N 53.4 N N
Huang et al.
(2008)
Tipranavir + ritanovir 48 weeks 48.0 (11.3) 48.2 NM N 47.8 (10.5) 49.2 NM N
Boosted comparitor
protease inhibitor
48 weeks 47.1 (10.9) 46.8 NM N 46.9 (10.3) 48.6 NM N
Lafaurie et al.
(2008)
Maintenance of a stable
protease inhibitor-containing
regimen
48 weeks NR −1.04 NM N NR 0.00 NM N
Switch to efavirenz +
didanosine + emtricitabine
once-daily





400/200 mg twice daily
4 weeks 49.44 52.06 Y Y 46.7 50.79 Y Y
8 weeks 52.38 Y Y 51.34 Y Y
Deferred (week 4) substitution
with lopinavir/ritonavir
400/100 mg twice daily
4 weeks 50.32 49.71 N Y 48.25 48.03 N Y
8 weeks 51.12 N Y 50.02 Y Y
Nuesch et al.
(2009)
Continuous treatment 24 weeks 53.8 (6.6) 52.7 N N 51.7 (7.6) 52.7 Y Y
48 weeks 52.5 N N 52.5 Y Y
CD4-guided scheduled
treatment interruption
(CD4 threshold of 350 cells/μL
for interruption/re-initiation
of ARV therapy)
24 weeks 54.4 (6.3) 53.2 N N 49.1 (8.3) 48.1 Y Y




(7 cycles of 4 weeks
off/8 weeks on HAART)
4 weeks 54.2 (8.3) 54.2 N Y 54.0 (8.8) 53.56 N Y
12 weeks 55.55 N Y 57.45 Y Y




4 weeks 53.0 (11.5) 53.27 N Y 53.8 (15.7) 53.36 N Y
12 weeks 52.97 N Y 57.25 N Y
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Table 2 Summary of MOS-HIV physical and mental health summary scores in NNRTI clinical trials (Continued)






6 months 45.7 (11.0) 44.2 NR Y 49.2 (10.3)* 49.5 NR N




Enfuvirtide + ARTs 12 weeks NR 2.21 Y N/A NR 2.91 Y N/A
Levine et al.
(2008)
Epoetin alfa + iron
supplementation
(in addition to current
ART regimen)
MPD1 38.5 (12.0) 43.0 N N/A 42.4 (11.2) 47.8 N N/A




home visits by study
staff that re-supplied HAART
and other drugs, conducted
a pill count, and assessed
participants’ health
3 months 39.2 (9.8) 50.6 Y N/A 40.0 (11.2) 50.2 Y N/A
6 months 53.0 Y N/A 53.0 Y N/A
9 months 53.6 Y N/A 54.2 Y N/A
12 months 54.2 Y N/A 54.2 Y N/A
*significant difference in baseline scores (P=0.01).
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Of all MOS-HIV domains measured, only one significant
difference between groups was observed; compared to
CPI/r, TPV/r was associated with a small but significant
improvement in pain scores (+4.8 points; P<0.05). A study
by Lafaurie et al. (2008) [15] evaluated HIV-infected adults
receiving a PI-containing ARV regimen and compared
maintenance of the current PI-containing regimen versus
switch to a once-daily NNRTI-based regimen of EFV/ddI/
emtricitabine (FTC). Although a medium effect was
observed in the PHS score in the switch arm (mean
change −1.76, effect size 0.53), the difference in change
from baseline to 48 weeks in both PHS and MHS scores
was not statistically significant between treatment groups
(P=0.57 and P=0.42, respectively). Sprinz et al. (2006) [16]
evaluated the effect of substituting lopinavir/ritonavir
(LPV/r) for the PI component of a HAART regimen in pa-
tients experiencing treatment-related Grade-2 side effects.
Treatment arms in this study were immediate substitution
(IS) versus deferred (week 4) substitution (DS). At week 4,
patients in the IS group had improvement of 2.6 points in
the PHS score (from a baseline of 49.4; P<0.001) and a 4.1
point improvement in the MHS score (from a baseline of
46.7; P<0.001). Furthermore, at week 4, the effect size for
the between-group difference in PHS and MHS scores
were 0.45 and 0.56, respectively, suggesting moderate cli-
nically meaningful improvement in the IS group com-
pared to the DS group. The difference between the groups
was statistically significant (P<0.001 for both PHS and
MHS scores).
Two randomized controlled trials (RCTs) evaluated
continuous versus intermittent ARV therapy. A study by
Nuesch et al. (2009) [17] compared continuous ARV
treatment with scheduled treatment interruption (STI)
and showed no significant change in PHS over time orbetween groups. MHS scores were significantly higher in
the continuous treatment group than the STI group at
baseline, 24 weeks, and 48 weeks, but not at the final
visit. Furthermore, MHS scores significantly improved
over time in both groups (P=0.001), but the improve-
ment was not significantly different between groups
(P=0.17). In a RCT by Powers et al. (2006) [18], patients
receiving intermittent ARV therapy had significantly
higher PHS and MHS scores at baseline and during each
follow-up point compared to patients receiving conti-
nuous ARV therapy. Compared to baseline, a significant
improvement was observed in MHS score at weeks 12
and 40 in patients receiving intermittent ARV therapy;
no other significant changes over time were observed.
The final two RCTs did not distinguish between ARV
treatment regimens in reporting HRQL results. In a se-
condary analysis of Options in Management with An-
tiretrovirals (OPTIMA) data, Anis et al. (2009) [19]
evaluated several treatment regimens in multidrug resist-
ant HIV-infected adults and reported MOS-HIV scores
for all treatment regimens collectively at baseline and at
four follow-up time points, stratifying patients by pre-
sence or absence of AIDS-defining events (ADEs), ser-
ious adverse events (SAEs), and improvement in clinical
measures—CD4 count and viral load. Although signifi-
cance of MOS-HIV score changes over time was not
reported, PHS and MHS scores were significantly lower
for those that experienced SAEs or ADEs compared to
those who did not at most time points. Similarly, PHS
and MHS scores were significantly higher among those
with improvement in CD4 count compared to those
with no improvement (P≤0.01) [see Additional file 1:
Appendix]. A study by Wu et al. (2006) [20] compared a
Disease Management Assistance System (DMAS) with
education versus education only in HIV-infected adults.
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the groups at follow-up on all ten MOS-HIV domains,
there were significant differences at baseline on five of
the scales. The study concluded that the differences bet-
ween groups generally reflected a combination of im-
provement in the standard education arm and some
deterioration in the DMAS arm over time.
Non-randomized controlled trials
All three prospective non-RCTs evaluated a single treat-
ment arm. A study by Shalit et al. (2007) [21] evaluated
the addition of enfuvirtide (ENF, T-20) to ARV therapy
in treatment-experienced, enfuvirtide-naïve, HIV-infected
adults. Significant improvements were observed in the
least squares mean (LSM) change from baseline to week
12 scores among most MOS-HIV domains; social function
and role function were the only domains in which signifi-
cant improvements did not occur. A trial by Levine et al.
(2008) [22] evaluated the efficacy and safety of the admin-
istration of erythropoietin alfa in maintaining HRQL and
hemoglobin levels in anemic HIV-infected patients. In this
study, all domains of the MOS-HIV improved significantly
from baseline to day one of the maintenance phase (all
P<0.001, except role function P<0.05). Improvements in
HRQL scores were associated with improvements in
hemoglobin levels. Finally, a study by Stangl et al. (2007)
[23] evaluated the initiation of HAART and weekly home
visits in treatment-naïve HIV-infected adults in rural
Uganda. At each follow-up visit, PHS and MHS scores
were significantly higher than baseline scores (P<0.001)
and HRQL improvement closely tracked improvements in
CD4 cell count.
EQ-5D
The EQ-5D was administered in five HIV trials (three
RCTs and two prospective observational studies) between
2001 and 2010. Overall, the EQ-5D was responsive to oc-
currences of adverse events and opportunistic infections,
with small-to-medium effect sizes (range 0.3–0.5) in each
of its five dimensions. In addition, the EQ-5D demon-
strated medium effect sizes in all dimensions in aTable 3 Effect sizes observed in EQ-5D items in a
prospective study of enfuvirtide
EQ-5D dimension Mean change % change Effect size
Mobility −0.4 −26.67% −0.4
Self-care −0.2 −16.67% −0.3
Usual activities −0.4 −23.53% −0.5
Pain/discomfort −0.3 −17.65% −0.3
Anxiety/depression −0.5 −26.32% −0.4
Mean change calculated as final score – baseline score. % change calculated
as [(final score - baseline score) / baseline score] x 100. Effect size calculated as
(final score – baseline score) / standard deviation of baseline score.prospective enfuvirtide study (Table 3). Only one study
measured and reported the change in EQ-5D scores over
time. A summary of key findings is presented below,
group by study design; additional details of each of the 5
trials are available in the Additional file 1: Appendix.Randomized controlled trials
One clinical trial used the EQ-5D to assess quality of life
in a study aimed to determine whether side effects of
PI-containing ARV therapy, such as lipodystrophy,
dyslipidemia, and insulin resistance, are reversible with
continued HIV suppression following PI substitution
[24]. Eighty-one treatment-experienced patients were
randomized to either continue their current PI +
nucleoside-based therapy (control patients) or switch the
PI-component of their regimen to abacavir/nevirapine/
adefovir (plus hydoxyurea at week 4). In this study, both
patient-assessed and physician-assessed EQ-5D scores
were reported. The change in patient-assessed EQ-5D
scores from baseline to 24-week follow-up (−6 in control
group versus +8 in switch group) was not statistically
significant (P=0.074), while the change in physician-
assessed EQ-5D scores (−7 in control group versus +8 in
switch group) was statistically significant (P=0.016).
In a secondary analysis of OPTIMA data, Anis et al.
(2009) [19] evaluated several treatment regimens in
multidrug-resistant HIV-infected adults and reported
EQ-5D scores for all treatment regimens collectively at
baseline and at four follow-up time points, stratifying
patients by presence or absence of ADEs, SAEs, and im-
provement in clinical measures—CD4 count and viral
load. Similar to the findings of the MOS-HIV, EQ-5D
scores were significantly lower for those that experi-
enced SAEs or ADEs compared to those who did not at
most time points (all with the exception of ADE at time
point one P≤0.01). Also similar to the MOS-HIV results,
EQ-5D scores were significantly higher among patients
with improvement in CD4 count compared to those
with no improvement (P≤0.05).
A study by Wu et al. (2002) [4] compared valacyclovir
and acyclovir as prophylactic regimens for cytomegalo-
virus, stratifying EQ-5D results by presence or absence
of adverse events, without regard to treatment allocation
in the study. At baseline, no patients had the lowest pos-
sible EQ-5D score, while 28.2% scored the highest at-
tainable score of 1.0 and 75% of patients scored between
0.72 and 1. Effect size was moderate (0.40) for the EQ-
5D Index among patients experiencing an adverse event
(Figure 1); effect sizes for all other dimensions were
“small” and insignificant (0.05–0.20). In a subgroup of
patients experiencing an opportunistic infection (OI),
the EQ-5D index score demonstrated no change (0.60












Figure 1 Sensitivity of EQ-5D VAS to detect change in HRQL
with experience of an opportunistic infection.
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after OI diagnosis (P<0.01).
Prospective observational studies
A small study (n=16) by Bucciardini et al. (2008) [25]
evaluated the addition of enfuvirtide to a selected opti-
mized background ARV regimen in HIV-infected adults.
On average, the EQ-5D profile of the enrolled subjects
improved over time during the six-month follow-up
(P value not reported). Effect size was moderate (0.50)
for the Usual Activities domain at three and six months;
effect sizes for all other dimensions were “small”
(0.20–0.40) at both three and six months. A similar but
larger study (n=102) evaluating the addition of enfu-
virtide to a selected optimized background ARV regimen
was conducted in South Africa [26]. In this study, mean
EQ-5D scores did not change significantly during the
18-month follow-up and effect sizes (0.03–0.05) were
negligible.
Discussion
Over a recent five-year period, the MOS-HIV Health
Survey has been one of the most widely used PRO in-
struments in treatment trials for people with HIV dis-
ease. The EQ-5D has also been used, though not as
frequently. However, given recent regulatory guidance,
we expect these PRO instruments, and others, will be
used more in future clinical trials.
It is important to note that it is sometimes difficult to
demonstrate PRO responsiveness in the setting of a clin-
ical trial, since there are not always actual differences
between groups to be detected. Many recent HAART
studies in ARV-naïve patients are designed as equivalencestudies; thus, the effect of HIV disease in the study arms
may be expected to be quite similar. In addition, if the
newer HAART regimens used in these patient groups
have similar side effect profiles, except for SAEs that lead
to study discontinuation, measurable differences in HRQL
would not be expected. Several of the studies that we
reviewed used highly effective treatments with similar side
effect profiles in both arms. In these cases, it appears
that the observed lack of change in PRO scores in
the specific studies may be due more to the treat-
ments used in the studies than to the sensitivity of
the PRO instruments. However, overall examination
of published trial results indicates that both of these
PRO measures are responsive to changes in clinical
condition in the intended patient population.
Overall, we observed that the MOS-HIV was respon-
sive to changes in HIV-infected patients initiating ARV
therapy for the first time. Although we did not find simi-
lar responsiveness among treatment-experienced pa-
tients, it is important to note that only three studies
were reviewed and in each of them only minor ARV
therapy modifications were made. Two studies evaluated
the clinical and patient-reported effects of treatment
interruption [17,18] and the third study compared two
boosted PI regimens, which are expected to have similar
side effects [14]. Therefore, we are unable to conclude
from our review whether or not the MOS-HIV is sensi-
tive to more substantial ARV therapy modifications in
treatment-experienced patients, such as switching from
an NNRTI-based regimen to a PI-based regimen.
Although a smaller literature base is available for the
EQ-5D, this instrument has demonstrated responsive-
ness to ARV therapy changes [25], occurrences of ADEs
[19], AEs [4,19], and OIs [4]. Studies have not been
conducted that showed differences in change scores be-
tween treatment groups. Advantages of the EQ-5D in-
clude its low administrative burden (five items with
an optional VAS) and its ability to generate indirect
health utility values for use in economic models.
Conclusions
Our systematic literature review suggests that both
the MOS-HIV and EQ-5D instruments are responsive
to clinical changes in HIV-infected patients. These
two instruments may complement each other and
researchers should consider using them together in
clinical trials to obtain HIV-specific HRQL and utility
measures without excessive respondent burden.
Additional file
Additional file 1: PRO Responsiveness Manuscript_Appendix Table
A and B.doc. Data extraction tables for MOS-HIV and EQ-5D.
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